How have the shares performed?
Edgewise Therapeutics Inc. (EWTX) saw downtrend of -2.08% in the recent trading with $24.99 being its most recent. The current price level -38.28% lower than the highest price of $40.49 marked by the stock while trading over the past 52-weeks, whereas it is 18.63% higher than the lowest price of $21.07 the company dropped to over past 52-weeks. The latest news story on EWTX appeared in Business Wire under the title “Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skeletal Muscle Conference” on Jun-22-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -16.00% below one month high and is +0.56% above of the lowest during that time. Looking into the simple moving average, Edgewise Therapeutics Inc. (EWTX)’s stock stands at a SMA-50 of $27.34 while that of 5-day is reading $26.09.
Edgewise Therapeutics Inc. Earnings – What Happened With EWTX
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
EWTX – Edgewise Therapeutics Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 1.56 million. EWTX does have institutional investors; and they hold 98.90% of the stock.
Edgewise Therapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 4 new insider purchases involving 9,742,562 shares. On the other hand, EWTX declared 0 shares have been sold in 0 insider transactions over the past three months.
As on Mar 30, 2021, Orbimed Advisors LLC. was the top most holder in Edgewise Therapeutics Inc. (NASDAQ:EWTX) with an ownership of 13.94 million shares of the company or 28.31% of the stake worth $453.2 million. The filing also reveals Novo Holdings A/S as the second largest holder in the company with a control over 11.34% of the outstanding shares. Its stake is worth $181.58 million for having 5.59 million shares in hand.
Deerfield Management Company, L.P. (Series C) also came holding a key position in the company during the recent quarter and it now holds 7.99% of the outstanding shares. With this there are now 36 institutions which have possession in EWTX’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Edgewise Therapeutics Inc. was 29.86 while posting a debt to equity ratio of 0.00.